JP4281075B2 - カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法 - Google Patents

カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法 Download PDF

Info

Publication number
JP4281075B2
JP4281075B2 JP53035696A JP53035696A JP4281075B2 JP 4281075 B2 JP4281075 B2 JP 4281075B2 JP 53035696 A JP53035696 A JP 53035696A JP 53035696 A JP53035696 A JP 53035696A JP 4281075 B2 JP4281075 B2 JP 4281075B2
Authority
JP
Japan
Prior art keywords
reaction
alkyl
mmol
nmr
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53035696A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11503156A5 (2
JPH11503156A (ja
Inventor
ヘネガー，ケビン・イー
シー，ジョン・シー
Original Assignee
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Publication of JPH11503156A publication Critical patent/JPH11503156A/ja
Publication of JPH11503156A5 publication Critical patent/JPH11503156A5/ja
Application granted granted Critical
Publication of JP4281075B2 publication Critical patent/JP4281075B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Paper (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
JP53035696A 1995-04-07 1996-04-01 カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法 Expired - Fee Related JP4281075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41964395A 1995-04-07 1995-04-07
US08/419,643 1995-04-07
PCT/US1996/004163 WO1996031513A1 (en) 1995-04-07 1996-04-01 Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007277903A Division JP2008069170A (ja) 1995-04-07 2007-10-25 カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法

Publications (3)

Publication Number Publication Date
JPH11503156A JPH11503156A (ja) 1999-03-23
JPH11503156A5 JPH11503156A5 (2) 2004-07-22
JP4281075B2 true JP4281075B2 (ja) 2009-06-17

Family

ID=23663114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53035696A Expired - Fee Related JP4281075B2 (ja) 1995-04-07 1996-04-01 カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法
JP2007277903A Pending JP2008069170A (ja) 1995-04-07 2007-10-25 カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007277903A Pending JP2008069170A (ja) 1995-04-07 2007-10-25 カンプトテシン誘導体（ｃｐｔ−１１）および関連化合物を製造するための新規な中間体および方法

Country Status (25)

Country Link
US (3) US6121451A (2)
EP (1) EP0835257B1 (2)
JP (2) JP4281075B2 (2)
KR (1) KR100423627B1 (2)
CN (5) CN1241926C (2)
AT (1) ATE224899T1 (2)
AU (1) AU717179B2 (2)
CA (1) CA2214793C (2)
CZ (1) CZ297862B6 (2)
DE (1) DE69623960T2 (2)
DK (1) DK0835257T3 (2)
ES (1) ES2183943T3 (2)
HK (2) HK1054234B (2)
HU (1) HUP9801436A3 (2)
IL (1) IL117684A (2)
MX (1) MX9707706A (2)
NO (2) NO320482B1 (2)
NZ (1) NZ306664A (2)
PL (2) PL186446B1 (2)
PT (1) PT835257E (2)
RU (1) RU2164917C2 (2)
SI (1) SI0835257T1 (2)
TW (1) TW438775B (2)
WO (1) WO1996031513A1 (2)
ZA (1) ZA962747B (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG88737A1 (en) * 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
WO2000020405A1 (en) * 1998-10-07 2000-04-13 Mitsubishi Chemical Corporation Mixtures of optical isomers of 1,2-disubstituted-2,3-epoxypropanes, process for producing the same, pesticides containing the same as the active ingredient and intermediates thereof
FR2794123B1 (fr) 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6855294B2 (en) * 2000-11-22 2005-02-15 Resonance, Inc. Apparatus and methods for efficient generation of chlorine dioxide
TWI245768B (en) 2001-02-21 2005-12-21 Yakult Honsha Kk Process for synthesizing camptothecin related compound(s)
US6723853B2 (en) * 2001-08-27 2004-04-20 University Of Pittsburgh Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins
JP3839813B2 (ja) * 2002-04-17 2006-11-01 ファルマシア コーポレイション カンプトテシン誘導体の調製に有用な化合物
US7151179B2 (en) 2003-05-12 2006-12-19 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
CZ299329B6 (cs) 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CN1852740B (zh) * 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CZ299593B6 (cs) 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
US20050267141A1 (en) * 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
ATE446299T1 (de) 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
EP1928883B1 (en) 2005-02-08 2013-10-30 Fermion Oy Process for the preparation of irinotecan hydrochloride
ES2430375T3 (es) 2005-02-08 2013-11-20 Fermion Oy Procedimiento para la producción de cloruro de [1,4']bipiperidinil-1'-carbonilo o su clorhidrato
TWI375678B (en) * 2005-06-09 2012-11-01 Yakult Honsha Kk A method of preparation of a tricyclic ketone
EP1803725A1 (en) * 2005-12-13 2007-07-04 W.C. Heraeus GmbH Methods for preparing irinotecan
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2008066902A2 (en) 2006-11-30 2008-06-05 Nektar Therapeutics Al, Corporation Method for preparing a polymer conjugate
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
EP2664632A1 (en) * 2008-07-31 2013-11-20 The Lubrizol Corporation Novel copolymers and lubricating compositions thereof
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010025337A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
JP2012503602A (ja) 2008-09-23 2012-02-09 ネクター セラピューティックス 対象において持続的治療薬濃度を実現するための組成物及び方法
US20100098654A1 (en) * 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2012032531A1 (en) * 2010-09-06 2012-03-15 Avra Laboratories Pvt. Ltd. Process for the manufacture of irinotecan hydrochloride by total synthesis
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3371192B1 (en) 2015-10-27 2020-06-03 California Pacific Medical Center Podophyllotoxin derivatives and their use
US10087194B2 (en) * 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN105965710B (zh) * 2016-06-28 2019-03-22 常州大学 一种硅棒金钢线切割树脂板的制备方法及应用
US11434196B2 (en) 2019-01-15 2022-09-06 Laurus Labs Limited Process for preparation of 2-Amino-5-hydroxy propiophenone
CN112300184B (zh) * 2019-08-02 2022-12-06 华东师范大学 一种三元环化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217499A (en) * 1975-07-31 1977-02-09 Nippon Chemiphar Co Ltd Preparation of mappicine
DE3682874D1 (de) * 1985-10-21 1992-01-23 Daiichi Seiyaku Co Pyranoindolizinderivate und verfahren zu ihrer herstellung.
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
US5405963A (en) * 1993-06-10 1995-04-11 Smithkline Beecham Corporation Process for asymmetric total synthesis of camptothecin analogues
GB9316352D0 (en) * 1993-08-06 1993-09-22 Erba Carlo Spa Process for the preparation of 9-amino camptothecin
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin

Also Published As

Publication number Publication date
CN100537538C (zh) 2009-09-09
CN1241926C (zh) 2006-02-15
AU717179B2 (en) 2000-03-16
CN1181083A (zh) 1998-05-06
NO20050408L (no) 1997-12-08
IL117684A (en) 2002-02-10
PT835257E (pt) 2003-01-31
DK0835257T3 (da) 2003-02-03
US6444820B1 (en) 2002-09-03
CN1434046A (zh) 2003-08-06
ES2183943T3 (es) 2003-04-01
CA2214793C (en) 2009-10-20
CN1434043B (zh) 2010-04-28
CZ311097A3 (cs) 1998-03-18
HK1054236B (zh) 2010-02-05
HUP9801436A2 (hu) 1998-10-28
CN1434037A (zh) 2003-08-06
PL322651A1 (en) 1998-02-16
ATE224899T1 (de) 2002-10-15
SI0835257T1 (en) 2003-04-30
PL186564B1 (pl) 2004-01-30
HK1054236A1 (zh) 2003-11-21
NO974608D0 (no) 1997-10-06
DE69623960D1 (de) 2002-10-31
CN1434043A (zh) 2003-08-06
IL117684A0 (en) 1996-07-23
WO1996031513A1 (en) 1996-10-10
HK1054234A1 (zh) 2003-11-21
NO974608L (no) 1997-12-08
NZ306664A (en) 1999-11-29
NO329776B1 (no) 2010-12-13
NO320482B1 (no) 2005-12-12
US6235907B1 (en) 2001-05-22
DE69623960T2 (de) 2003-06-05
CN100396682C (zh) 2008-06-25
AU5527896A (en) 1996-10-23
TW438775B (en) 2001-06-07
JP2008069170A (ja) 2008-03-27
PL186446B1 (pl) 2004-01-30
KR19980703691A (ko) 1998-12-05
KR100423627B1 (ko) 2004-07-27
HK1009448A1 (en) 1999-09-10
EP0835257B1 (en) 2002-09-25
CA2214793A1 (en) 1996-10-10
CN1100058C (zh) 2003-01-29
US6121451A (en) 2000-09-19
HK1054234B (zh) 2010-12-24
MX9707706A (es) 1997-12-31
CN1434044A (zh) 2003-08-06
ZA962747B (en) 1998-04-06
HK1055118A1 (zh) 2003-12-24
HK1055119A1 (en) 2003-12-24
CZ297862B6 (cs) 2007-04-18
HUP9801436A3 (en) 1998-11-30
JPH11503156A (ja) 1999-03-23
EP0835257A1 (en) 1998-04-15
RU2164917C2 (ru) 2001-04-10

Similar Documents

Publication Publication Date Title
US6444820B1 (en) Process for the manufacture of camptothecin derivatives
EP0758333B1 (en) Intermediates in pharmaceutical camptothecin preparation
JP5893156B2 (ja) 新規な抗ウイルス性ピロロピリジン誘導体及びその製造方法
KR20190085004A (ko) 트리아졸로피리딘 화합물의 제조 방법
IL314714A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK1055118B (en) Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds
JPH0959254A (ja) ２−ヒドロキシピリジン類および／または２（１ｈ）−ピリドン類の製造法
US6559309B2 (en) Preparation of a camptothecin derivative by intramolecular cyclisation
HK1052687B (en) Preparation of a camptothecin derivative by intramolecular cyclisation

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071025

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071102

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20070925

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20071220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090303

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090306

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120327

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees